The Efficacy of Ibrutinib in Two Patients with Chronic Lymphocytic Leukemia: A Case Report

Mehrnoosh Aeinfar¹, Mehrdad Payandeh¹ and Edris Sadeghi^2,

¹Department of Nursing, Borujerd Branch, Islamic Azad University, Borujerd, Iran

²Department of Hematology and Medical Oncology, Kermanshah University of Medical Sciences, Kermanshah, Iran

Cite this paper:
Mehrnoosh Aeinfar, Mehrdad Payandeh and Edris Sadeghi. The Efficacy of Ibrutinib in Two Patients with Chronic Lymphocytic Leukemia: A Case Report. American Journal of Cancer Prevention. 2017; 5(3):44-45. doi: 10.12691/ajcp-5-3-6

Abstract

Ibrutinib known as a new development revolution in therapy of lymphoproliferative disorders like in patients with relapsed and refractory CLL. Aim of this study is efficacy of Ibrutinib in patients with CLL. First patient was 86-year-old man had a diagnosis of CLL established in January 2016. Peripheral blood smear showed 128900 WBC cells that 77 percent of it was absolute lymphocyte (99253 cells). He began receiving ibrutinib at daily dose of 140 mg by in 2016. Second patient was 58-year-old man was diagnosed with lymphoprolifirative disorder (CLL) at oncology clinic in January 2014. At diagnosis time, WBC count was 24000 and platelet count was 203000 and hemoglobin was 14.5 g/dl. Ibrutinib hold for two months and she treated with IVIG. After increased platlate count we try with a new policy consist of chlorambucil and procarbazine as a new regimen. She is stable for 9 months and we decide to decrease this combination, gradually. When in treatment of CLL you have limitation in old drug is better try a new class of target drug with low dosage, and increase to the standard dosage step by step. In this case causes drug induced thrombocytopenia.

Keywords:
CLL Ibrutinib Platelet WBC

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Payandeh M, Sadeghi M, Sadeghi E. Cholorambucil versus Cholorambucil Plus Prednisolone as First-Line Therapy of Chronic Lymphocytic Leukemia in West of Iran. Iran J Cancer Prev. 2015; 8(2): 94-9.
[2]	Cheng S, Ma J, Guo A, Lu P, Leonard JP, Coleman M, Liu M, Buggy JJ, Furman RR, Wang YL.. BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity. Leukemia. 2014; 28: 649-57.
[3]	Byrd JC, Furman RR, Coutre SE, Burger JA, Blum KA, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Shaw Y, Bilotti E, Zhou C, James DF, O'Brien S.Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood 2015; 125(16): 2497-2506.
[4]	Wang ML, Blum KA, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Zhang L, Baher L, Cheng M, Lee D, Beaupre DM, Rule S. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood 2015; 126(6): 739-745.
[5]	Burger JA. Nurture versus nature: the microenvironment in chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2011; 2011: 96-103.
[6]	Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, Kolibaba KS, Furman RR, Rodriguez S, Chang BY, Sukbuntherng J, Izumi R, Hamdy A, Hedrick E, Fowler NH. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol2013; 31(1): 88-94.
[7]	Cheson BD, Byrd JC, Rai KR, Kay NE, O'Brien SM, Flinn IW, Wiestner A, Kipps TJ. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol. 2012; 30(23): 2820-2.